Abstract
Peroxisome proliferator-activated receptor alpha (PPAR??) regulates transcription of genes involved both in lipid and glucose metabolism as well as in inflammation. Fibrates are PPARα ligands used to normalize lipid and glucose parameters and exert antiinflammatory effects. In fact, fibrates have already been demonstrated to benefit metabolic syndrome, type 2 diabetes and cardiovascular diseases. This article reviews the mechanism of action and the functional roles of fibrates, emphasizing the factors modulating their capacity to activate PPARα and affecting their effectiveness. These factors may possibly explain the findings obtained in animal studies and clinical trials with fibrates which showed either untoward effects and/or inefficient hypolipidemic action of PPARα activation. We also discuss briefly the natural and synthetic agonists of PPARαwhich are currently being developed and supposedly display greater effectiveness and fewer adverse effects than fibrates.
Keywords: Peroxisome proliferator-activated receptor, fibrates, natural PPAR agonists, synthetic PPAR activators, metabolic syndrome, type 2 diabetes, cardiovascular disease
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Factors Modulating Fibrates Response: Therapeutic Implications and Alternative Strategies
Volume: 9 Issue: 3
Author(s): M. I. Panadero, M. C. Gonzalez, E. Herrera and C. Bocos
Affiliation:
Keywords: Peroxisome proliferator-activated receptor, fibrates, natural PPAR agonists, synthetic PPAR activators, metabolic syndrome, type 2 diabetes, cardiovascular disease
Abstract: Peroxisome proliferator-activated receptor alpha (PPAR??) regulates transcription of genes involved both in lipid and glucose metabolism as well as in inflammation. Fibrates are PPARα ligands used to normalize lipid and glucose parameters and exert antiinflammatory effects. In fact, fibrates have already been demonstrated to benefit metabolic syndrome, type 2 diabetes and cardiovascular diseases. This article reviews the mechanism of action and the functional roles of fibrates, emphasizing the factors modulating their capacity to activate PPARα and affecting their effectiveness. These factors may possibly explain the findings obtained in animal studies and clinical trials with fibrates which showed either untoward effects and/or inefficient hypolipidemic action of PPARα activation. We also discuss briefly the natural and synthetic agonists of PPARαwhich are currently being developed and supposedly display greater effectiveness and fewer adverse effects than fibrates.
Export Options
About this article
Cite this article as:
Panadero I. M., Gonzalez C. M., Herrera E. and Bocos C., Factors Modulating Fibrates Response: Therapeutic Implications and Alternative Strategies, Endocrine, Metabolic & Immune Disorders - Drug Targets 2009; 9 (3) . https://dx.doi.org/10.2174/187153009789044356
DOI https://dx.doi.org/10.2174/187153009789044356 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Urinary Steroids Measured by Modern Separation Techniques and Applied as Biomarkers in Stress Studies
Current Pharmaceutical Analysis Beta-Blocker Therapy for Septic Cardiac Shock: Fiction Or Realism?
Current Drug Therapy Cardiac Amyloid - A Hidden Contributor to Cardiac Dysfunction Following Cardiac Surgery: Case Report and Literature Review
Current Cardiology Reviews Present Insights on Cardiomyopathy in Diabetic Patients
Current Diabetes Reviews Takotsubo Syndrome: Clinical Manifestations, Etiology and Pathogenesis
Current Cardiology Reviews Cell-free DNA: Characteristics, Detection and its Applications in Myocardial Infarction
Current Pharmaceutical Design Effects of Endothelins on Cardiac and Vascular Cells: New Therapeutic Target for the Future?
Current Vascular Pharmacology Editorial:Circulating Biomarkers in Cardiovascular Diseases – A Field of Theoretical Research or Realistic Clinical Application?
Current Pharmaceutical Biotechnology The Clinical Problems of Hypertension Treatment in Hemodialysis Patients
Current Vascular Pharmacology Flavones as a Privileged Scaffold in Drug Discovery: Current Developments
Current Organic Synthesis Development of Novel Cardiovascular Therapeutics From Small Regulatory RNA Molecules - An Outline of Key Requirements
Current Pharmaceutical Design Serum Collagen Markers and Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets Therapeutic Approach for Neuronal Disease by Regulating Reninangiotensin System
Current Hypertension Reviews Markers of Arrhythmogenic Risk in Hypertensive Subjects
Current Pharmaceutical Design Urotensin-II Receptor: A Double Identity Receptor Involved in Vasoconstriction and in the Development of Digestive Tract Cancers and other Tumors
Current Cancer Drug Targets Application of G-CSF in Congestive Heart Failure Treatment
Current Cardiology Reviews The Potential of Secondary Metabolites from Plants as Drugs or Leads Against Protozoan Neglected Diseases – Part I
Current Medicinal Chemistry The ErbB Receptors and their Ligands in Cancer: An Overview
Current Drug Targets Pathogenesis of Age-Related Cataract: A Systematic Review of Proteomic Studies
Current Proteomics Atherosclerotic and Non-Atherosclerotic Coronary Heart Disease in Women
Current Medicinal Chemistry